Credits: 大臣官房人事課 (Secrétariat du ministre / Division du personnel, MEXT — Japanese Ministry of Education, Culture, Sports, Science and Technology) / Wikimedia Commons — CC BY 4.0.
On October 6, 2025 in Stockholm, the Nobel Assembly honored Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi for illuminating peripheral immune tolerance: discovery of regulatory T cells and the key role of the FOXP3/Foxp3 gene. Their work explains how immunity brakes itself without self-destructing and opens clinical avenues, from autoimmune diseases to transplants and cancer.
Peripheral Immune Tolerance: What the Nobel Assembly Honored
On October 6, 2025, in Stockholm, the Nobel Assembly at the Karolinska Institutet awarded the 2025 Nobel Prize in Physiology or Medicine to Mary E. Brunkow (Institute for Systems Biology, Seattle), Fred Ramsdell (Sonoma Biotherapeutics, San Francisco) and Shimon Sakaguchi (Osaka University) “for discoveries concerning peripheral immune tolerance.” The official announcement states that their work revealed regulatory T cells (treg cells), true “guardians” that prevent the immune system from running amok against our own tissues, and identified the role of the FOXP3 gene as a keystone of their development. The gene is spelled Foxp3 in mouse and FOXP3 in human.
The prize (worth 11 million Swedish kronor) recognizes a series of discoveries spread over nearly 30 years: demonstrating a T population with a braking function (1995), identifying a master gene (FOXP3) whose mutation triggers severe autoimmunity (2001), and then showing that this gene governs Treg formation (2003).
Treg Cells: How “Guardian” Cells Keep Balance
To stay healthy, immunity walks a tightrope. You must attack microbes and spare the body. For a long time, it was thought this balance relied mainly on drastic selection in the thymus (central tolerance). The laureates illuminated the other side, called peripheral tolerance: beyond the thymus, regulatory T cells patrol and calm excessive responses.
Concretely, Treg cells moderate the activity of other effector T lymphocytes. They use an arsenal of chemical signals and cellular contacts to quench inflammation when it threatens to spiral. Without them, our bodies could suffer autoimmune reactions such as type 1 diabetes, rheumatoid arthritis or lupus. There is also a risk of transplant rejection, complicating transplantation. Conversely, in oncology, some tumors exploit these cells to avoid detection. Consequently, this can impose unwanted brakes on cancer treatment. Depending on the context, Treg cells can also limit certain pro-tumor inflammations.
Simple image: think of the immune system as a car. Defenses are the accelerator; Treg cells, the brake. Without a brake, you go off the road; with a stuck brake, you don’t move forward.
FOXP3: The Master Code of Regulatory T Lymphocytes
At the heart of the story, one gene: FOXP3. In 2001, Mary E. Brunkow and Fred Ramsdell showed that a mutation of this gene, found in a mouse line called “scurfy”, causes fulminant autoimmunity. The human equivalent is IPEX syndrome (Immunodysregulation Polyendocrinopathy Enteropathy X-linked), rare but life-threatening in infants.
FOXP3 encodes a transcription factor: a conductor protein that activates or represses sets of genes. In 2003, Shimon Sakaguchi connected the dots: FOXP3 is essential for the development and function of Treg cells. Without this factor, there is no reliable immune brake.
From the “Scurfy” Mouse to IPEX Syndrome: What Rare Diseases Reveal
Rare diseases act here like spotlights. In the “scurfy” mouse, lacking a functional FOXP3, the body self-destructs: dermatitis, visceral lesions, cachexia. In humans, IPEX syndrome — due to FOXP3 mutations on the X chromosome — causes severe enteropathy, endocrine dysfunctions (neonatal diabetes, thyroiditis), and recurrent infections. These extreme presentations provided decisive evidence: when FOXP3 fails, Treg cells do not form properly and tolerance collapses.
A Scientific Fable: The Immune System’s Close Protection
There are scenes of lab literature in this story. 1995: amid polite indifference, Shimon Sakaguchi described CD25+ T lymphocytes (CD25 marker of Treg cells) capable of preventing autoimmunity. 2001: two researchers, Brunkow and Ramsdell, dissect a genetic riddle; they named the gene Foxp3. 2003: the loop is closed, the molecular brake meets the cell population. Underlying it all, a simple idea: immunity is not just an assault army, it’s an expeditionary force with police.
What This Changes for Patients: Today
Do not oversell: clinical immunology advances step by step. Today, the Treg concept already helps explain diseases (e.g., IPEX), reclassify some immunodeficiencies, and refine transplant monitoring. Teams are exploring markers (including FOXP3) to stratify patients or anticipate transplant rejection.
In Treg transfer (cells expanded and reinfused), trials assess safety, dose, and persistence of these cells in patients with autoimmune diseases or transplants. Other strategies test drugs that increase or steer Treg cells in vivo (e.g., combinations with low-dose IL-2). Some approaches improve intermediate endpoints, but no Treg-based treatment is yet standard.
Treg and Cancer Immunotherapy: Tomorrow
Tomorrow, modulating Treg cells could become a therapeutic tool with two directions:
- Strengthen the brake to calm autoimmune diseases (type 1 diabetes, rheumatoid arthritis, multiple sclerosis), protect organ or marrow transplants.
- Loosen the brake in oncology, in combination with immunotherapies (anti-PD-1, anti-CTLA-4), to amplify the antitumor response when tumors hide behind overzealous Treg cells.
Limitations and precautions: manipulating Treg cells is not trivial. These cells are plastic and their environment (microbiota, cytokines) influences their fate. Protocols must be secured to ensure efficacy and avoid shifts toward dangerous pro-inflammatory responses. It will also be essential to monitor the risk of infections that may occur with treatments. Finally, precise indications must be defined without promising a cure, to manage expectations.
A Dawn Announcement… and a Human Wink
On Monday October 6, the announcement came early in Stockholm… and in the middle of the night on the U.S. West Coast. Fred Ramsdell was unreachable: colleagues say he was likely hiking, phone off. Science sometimes follows timelines that don’t line up with time zones. A wry note, not mocking: “Fred unaware” — immunity, meanwhile, watches ceaselessly.
Why Now?
Because these discoveries opened a field. Peripheral tolerance has become a pillar of modern immunology. It feeds clinical programs in autoimmunity, transplantation and cancer. It reconciles two views of immunity: central selection (thymus) and peripheral surveillance (Treg cells). By honoring Brunkow, Ramsdell and Sakaguchi, the jury also salutes a method: back-and-forth basic/clinical work, genetics and physiology, mouse and human.
Timeline
- 1995: Shimon Sakaguchi describes a T population (marker CD25, CD25 marker of Treg cells) that prevents autoimmunity.
- 2001: Mary E. Brunkow and Fred Ramsdell identify FOXP3 as the cause of severe autoimmunity (“scurfy”) and its human equivalent (IPEX).
- 2003: the link is consolidated: FOXP3 governs Treg development.
- 2025: the Nobel honors these milestones; clinical trials of Treg modulation multiply.
Sources for confirmation: Popular information ; Scientific background.
Patient Education: Simple Questions, Clear Answers
What is a Treg? A specialized T lymphocyte that brakes other immune cells when they risk harming the body.
How is it different from other T cells? Effector T cells attack; Treg cells calm. Both are necessary.
What is FOXP3? A gene that programs the birth and function of Treg cells. When mutated, tolerance collapses (e.g., IPEX in children).
Is this a treatment today? Not yet in routine care. Trials are testing Treg transfers or drugs that modulate their number and action. Patients may benefit from better understanding of diseases and finer follow-up.
And for cancer? Some tumors hijack Treg cells to brake immunity. Trials aim to reduce that braking, often alongside other immunotherapies.